Ustekinumab in the Treatment of Erythema Nodosum with Underlying Crohn’s Disease: A Case Report
Main Article Content
Keywords
crohn's disease, ustekinumab, erythema nodosum
Abstract
Erythema nodosum (EN) is a septal panniculitis characterized by raised, tender, red or purple lesions with a diameter of 1-5 cm. It is commonly treated with corticosteroids and can be an extra-intestinal manifestation of Crohn’s disease (CD). CD can be treated with ustekinumab, a monoclonal antibody that targets the p-40 subunit of the interleukin-12 (IL-12) and interleukin-23 (IL-23). A 78-year-old woman with erythema nodosum and Crohn’s disease presented with multiple erythematous nodules, which had been recurring on both of her legs for decades. The patient had failed many traditional EN treatments and was prescribed off-label ustekinumab, resulting in resolution of EN. This finding suggests that ustekinumab may be a potential treatment for EN in patients who also have CD.
References
2. Jumani L, Kataria D, Ahmed MU, Shah MAA, Raja K, Shaukat F. The Spectrum of Extra-intestinal Manifestation of Crohn's Disease. Cureus. 2020;12(2):e6928. Published 2020 Feb 10. doi:10.7759/cureus.6928
3. Annese V. A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease. Saudi J Med Med Sci. 2019;7(2):66-73. doi:10.4103/sjmms.sjmms_81_18
4. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-1992. doi:10.1097/MIB.0000000000000392
5. Fleisher M, Marsal J, Lee SD, et al. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi:10.1007/s10620-018-4971-1
6. Weinstein M, Turner D, Avitzur Y. Erythema nodosum as a presentation of inflammatory bowel disease. CMAJ. 2005;173(2):145-146. doi:10.1503/cmaj.050201
7. Faulkes RE. Upper limb erythema nodosum: the first presentation of Crohn's disease. Clin Case Rep. 2014;2(5):183-185. doi:10.1002/ccr3.87
8. Chowaniec M, Starba A, Wiland P. Erythema nodosum - review of the literature. Reumatologia. 2016;54(2):79-82. doi:10.5114/reum.2016.60217
9. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773
10. Globig AM, Sommer NP, Wild K, et al. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol. 2021;11(1):1-12. doi:10.1016/j.jcmgh.2020.07.005
11. Ustekinumab. Package insert. Janssen Pharmaceutical Companies; 2020.
12. Spagnuolo R, Dastoli S, Silvestri M, et al. Anti-interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: A case report. Dermatol Ther. 2019;32(2):e12811. doi:10.1111/dth.12811
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.